KIMBERLY AMEZQUITA: Open Payments
NPI 1285270462 · ROCKWALL, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$947 in 21 payments from 11 companies in 2025. Trend: 2023 $118 · 2024 $176 · 2025 $947
Food & beverage: $848Education: $99
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 5 | $238 |
| AERIN MEDICAL INC. | 1 | $149 |
| AstraZeneca Pharmaceuticals LP | 2 | $141 |
| SANOFI-AVENTIS U.S. LLC | 1 | $99 |
| Regeneron Healthcare Solutions, Inc. | 3 | $88 |
| Smith+Nephew, Inc. | 1 | $59 |
| Optinose US, Inc. | 2 | $54 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $54 |
| ALK-Abello, Inc | 2 | $36 |
| Phadia US Inc. | 1 | $16 |
Products named: DUPIXENT, VIVAER STYLUS, TEZSPIRE, TULA, Xhance, NEFFY, Ragwitek, ImmunoCAP.
Industry payments across TX — which companies pay providers there.
